Valeant Pharmaceuticals (VRX) Tops Estimates

Valeant Pharmaceuticals International, Inc. (VRX) shares are up $27.07 to $200.33 in morning trading Monday after the company reported its fourth quarter earnings results.

The multinational specialty pharmaceutical firm reported non-GAAP earnings of $2.58 per share on revenues of $2.28 billion, up 10.5% from a year ago. Analysts were expecting EPS of $2.56 on revenues of $2.23 billion. Total 2014 revs came in at $8.3 billion; an increase of 43% over the prior year.

For Q1’15, VRX provided EPS guidance of at least $2.30 versus consensus of $2.27 per share. Separately, the Canadian drug maker today announced reaching a definitive agreement to acquire all of the outstanding common stock of Salix for $158.00 per share in cash.

On valuation measures, Valeant Pharmaceuticals International Inc. shares, which currently have an average 3-month trading volume of 1.9 million shares, trade at a trailing-12 P/E of 135.27. The median Wall Street price target on the name is $183.00 with a high target of $200.00. Currently ticker boasts 16 ‘Buy’ endorsements, compared to 3 ’Holds’ and no ‘Sell’.

Profitability-wise, VRX has a t-12 profit and operating margin of 6.25% and 27.44%, respectively. The $67.25 billion market cap company reported $841.90 million in cash vs. $16.27 billion in debt in its most recent quarter.

VRX currently prints a one year return of about 17%, and a year-to-date return of around 21%.

The chart below shows where the equity has traded over the last 52 weeks.

Valeant Pharmaceuticals International Inc. develops pharmaceuticals, over-the-counter products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. The firm was founded in 1983 and is headquartered in Laval, Canada.

Be the first to comment

Leave a Reply

Your email address will not be published.